LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassays Compared for Diagnosis of Acute Murine Typhus Infections

By LabMedica International staff writers
Posted on 10 Sep 2019
Print article
Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Murine typhus is a disease transmitted by fleas and is caused by intracellular gram-negative bacteria called Rickettsia typhi, and manifested clinically with acute fever, chills, muscle pain, nausea, vomiting, stomach pain, cough and rash.

Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.

Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.

The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.

The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).

The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.